Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an ‘old’ strategy
Sign Up to like & getrecommendations! Published in 2021 at "BMJ Open Respiratory Research"
DOI: 10.1136/bmjresp-2020-000867
Abstract: Acute respiratory distress syndrome (ARDS) related to SARS-CoV-2 infection has some unusual characteristics that differentiate it from the pathophysiology described in the more ‘typical’ ARDS. Among multiple hypotheses, a close similarity has been suggested between… read more here.
Keywords: surfactant covid; pulmonary surfactant; covid; covid ards ... See more keywords
Lung ultrasound to guide the administration of exogenous pulmonary surfactant in respiratory distress syndrome of newborn infants: A retrospective investigation study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pediatrics"
DOI: 10.3389/fped.2022.952315
Abstract: Background Respiratory distress syndrome (RDS) is a common disease that seriously endangers the life and safety of newborns, especially premature infants. Exogenous pulmonary surfactant (PS) is the specific agent for the treatment of neonatal RDS.… read more here.
Keywords: surfactant; exogenous pulmonary; respiratory distress; distress syndrome ... See more keywords